Short Interest in Avalon GloboCare Corp. (NASDAQ:ALBT) Declines By 64.0%

Avalon GloboCare Corp. (NASDAQ:ALBT) was the recipient of a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 118,600 shares, a drop of 64.0% from the February 29th total of 329,000 shares. Currently, 2.5% of the shares of the company are sold short. Based on an average daily volume of 134,600 shares, the days-to-cover ratio is presently 0.9 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Avalon GloboCare stock. State Street Corp raised its stake in shares of Avalon GloboCare Corp. (NASDAQ:ALBT) by 70.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 19,120 shares of the company’s stock after acquiring an additional 7,920 shares during the quarter. State Street Corp owned approximately 0.19% of Avalon GloboCare worth $38,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 1.42% of the company’s stock.

Avalon GloboCare Price Performance

Shares of ALBT stock opened at $0.30 on Thursday. Avalon GloboCare has a one year low of $0.25 and a one year high of $2.45. The stock has a fifty day moving average price of $0.38 and a 200 day moving average price of $0.55.

Avalon GloboCare Company Profile

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.